The non-transplant treatment of myelodysplastic syndromes-what's on the horizon?
The therapeutic advance in the field of myelodysplastic syndromes (MDS) has evolved over the last decade with efficacy of hypomethylating agents and immunomodulatory drugs. Currently, several promising agents with diverse mechanisms of actions are in various stages of clinical development and will expand the therapeutic armamentarium for MDS. The advent of next generation sequencing technologies has improved the understanding of disease biology and this will drive further activity in the near future with new targeted therapies, like exploitation of newly identified molecular aberrations, such as SF3BI and STAG2, as a therapeutic target and also further refinement of existing treatments.